WO2016003169A3 - 세포 리프로그래밍 유도용 조성물 - Google Patents

세포 리프로그래밍 유도용 조성물 Download PDF

Info

Publication number
WO2016003169A3
WO2016003169A3 PCT/KR2015/006718 KR2015006718W WO2016003169A3 WO 2016003169 A3 WO2016003169 A3 WO 2016003169A3 KR 2015006718 W KR2015006718 W KR 2015006718W WO 2016003169 A3 WO2016003169 A3 WO 2016003169A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell reprogramming
present
composition
indazole derivative
compounds
Prior art date
Application number
PCT/KR2015/006718
Other languages
English (en)
French (fr)
Other versions
WO2016003169A2 (ko
Inventor
김용철
윌리엄스다런
정다운
이정은
서신애
박지연
Original Assignee
광주과학기술원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 광주과학기술원 filed Critical 광주과학기술원
Priority to US15/323,342 priority Critical patent/US10858321B2/en
Priority to CN201580036120.XA priority patent/CN106794172B/zh
Priority to PL15815352T priority patent/PL3165523T3/pl
Priority to ES15815352T priority patent/ES2768803T3/es
Priority to EP15815352.8A priority patent/EP3165523B1/en
Priority to JP2016575756A priority patent/JP6511075B2/ja
Publication of WO2016003169A2 publication Critical patent/WO2016003169A2/ko
Publication of WO2016003169A3 publication Critical patent/WO2016003169A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1323—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from skeletal muscle cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 세포 리프로그래밍 유도 조성물에 관한 것이다. 본 발명의 조성물에 포함되는 인다졸 유도체 화합물은 개선된 생물학적 프로파일(biological profile)을 나타냄과 동시에 효율적인 세포 리프로그래밍(re-programming)을 수행할 수 있다. 또한, 본 발명의 인다졸 유도체 화합물은 종래의 저분자 세포 리프로그래밍 유도 화합물(예컨대, 리버신 또는 BIO)과 달리 세포독성(cytotoxcicity)를 나타내지 않아 임상 적용시 세포치료제 시장에서의 고성장을 기대할 수 있다. 한편, 종래의 인다졸 유도체(indazole derivatives) 화합물은 세포 리프로그래밍 용도로서 전혀 알려진 바 없으며, 본 발명의 화합물의 경우 종래의 인다졸 유도체 화합물과 비교하여 세포독성(cytotoxicity)이 없거나 현저히 낮으면서도 세포 리프로그래밍 능력은 매우 우수하다.
PCT/KR2015/006718 2014-07-01 2015-06-30 세포 리프로그래밍 유도용 조성물 WO2016003169A2 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US15/323,342 US10858321B2 (en) 2014-07-01 2015-06-30 Composition for inducing cell reprogramming
CN201580036120.XA CN106794172B (zh) 2014-07-01 2015-06-30 细胞重编程诱导用组合物
PL15815352T PL3165523T3 (pl) 2014-07-01 2015-06-30 Kompozycja do indukowania przeprogramowania komórek
ES15815352T ES2768803T3 (es) 2014-07-01 2015-06-30 Composición para inducir la reprogramación celular
EP15815352.8A EP3165523B1 (en) 2014-07-01 2015-06-30 Composition for inducing cell reprogramming
JP2016575756A JP6511075B2 (ja) 2014-07-01 2015-06-30 細胞リプログラミング誘導用組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140081889A KR101731624B1 (ko) 2014-07-01 2014-07-01 세포 리프로그래밍 유도용 조성물
KR10-2014-0081889 2014-07-01

Publications (2)

Publication Number Publication Date
WO2016003169A2 WO2016003169A2 (ko) 2016-01-07
WO2016003169A3 true WO2016003169A3 (ko) 2016-06-16

Family

ID=55020061

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/006718 WO2016003169A2 (ko) 2014-07-01 2015-06-30 세포 리프로그래밍 유도용 조성물

Country Status (8)

Country Link
US (1) US10858321B2 (ko)
EP (1) EP3165523B1 (ko)
JP (1) JP6511075B2 (ko)
KR (1) KR101731624B1 (ko)
CN (1) CN106794172B (ko)
ES (1) ES2768803T3 (ko)
PL (1) PL3165523T3 (ko)
WO (1) WO2016003169A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240076059A (ko) 2022-11-23 2024-05-30 동서대학교 산학협력단 리버신을 유효성분으로 포함하는 아토피 예방, 개선 또는 치료용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014802A1 (en) * 2002-03-11 2004-01-22 Gilles Dutruc-Rosset Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof
US20090118278A1 (en) * 2002-08-02 2009-05-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of gsk-3
US8288425B2 (en) * 2001-10-26 2012-10-16 Aventis Pharmaceuticals Inc. Benzimidazoles
US8372850B2 (en) * 2006-11-02 2013-02-12 Vertex Pharmaceuticals Incorporated Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244907A (en) * 1992-03-26 1993-09-14 A. H. Robins Company, Incorporated Carbocyclic carboxylic acid amides and esters of azabicyclic compounds as gastric prokinetic, antiemetic, anxiolytic and antiarrhythmic agents
JP3289177B2 (ja) * 1995-07-07 2002-06-04 コニカ株式会社 新規な写真用カプラー及びハロゲン化銀カラー写真感光材料
DE19810018A1 (de) * 1998-03-09 1999-09-16 Bayer Ag Benzoheterocyclyloxime
US7642278B2 (en) * 2001-07-03 2010-01-05 Novartis Vaccines And Diagnostics, Inc. Indazole benzimidazole compounds
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
JP2006502133A (ja) * 2002-08-10 2006-01-19 アステックス、セラピューティックス、リミテッド サイクリン依存キナーゼ（ｃｄｋ）インヒビターとしての３−（カルボニル）１ｈ−インダゾール化合物
FR2845382A1 (fr) * 2002-10-02 2004-04-09 Sanofi Synthelabo Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
BRPI0508771A (pt) * 2004-03-25 2007-08-14 Memory Pharm Corp indazóis, benzotiazóis, benzoisotiazóis, benzisoxazóis, e a preparação e usos dos mesmos
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
EP2001480A4 (en) * 2006-03-31 2011-06-15 Abbott Lab Indazole CONNECTIONS
WO2008089307A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
CN101754956B (zh) * 2007-07-20 2014-04-23 内尔维阿诺医学科学有限公司 作为具有激酶抑制剂活性的取代的吲唑衍生物
CA2770320A1 (en) * 2009-08-10 2011-02-17 Epitherix, Llc Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
US9528087B2 (en) * 2009-10-31 2016-12-27 Genesis Technologies Limited Methods for reprogramming cells and uses thereof
SG189883A1 (en) * 2010-10-29 2013-06-28 Pfizer N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS
JP5868168B2 (ja) * 2011-12-28 2016-02-24 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
KR101539132B1 (ko) * 2012-01-20 2015-07-28 주식회사 스템랩 유전자 도입 없이 저분자성 물질을 이용하여 체세포로부터 심근세포를 유도하는 방법
US20130281399A1 (en) * 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
US20160096850A9 (en) * 2013-08-22 2016-04-07 Genentech, Inc. Alkynyl alcohols and methods of use
US9862717B2 (en) * 2014-08-22 2018-01-09 Merck Patent Gmbh Indazoles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288425B2 (en) * 2001-10-26 2012-10-16 Aventis Pharmaceuticals Inc. Benzimidazoles
US20040014802A1 (en) * 2002-03-11 2004-01-22 Gilles Dutruc-Rosset Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof
US20090118278A1 (en) * 2002-08-02 2009-05-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of gsk-3
US8372850B2 (en) * 2006-11-02 2013-02-12 Vertex Pharmaceuticals Incorporated Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE Chemical Abstract 1 April 2014 (2014-04-01), XP055362037, retrieved from STN Database accession no. 1577449-73-0 *

Also Published As

Publication number Publication date
KR101731624B1 (ko) 2017-05-04
EP3165523A4 (en) 2017-08-30
CN106794172B (zh) 2020-03-17
KR20160003965A (ko) 2016-01-12
US10858321B2 (en) 2020-12-08
JP6511075B2 (ja) 2019-05-15
EP3165523B1 (en) 2020-01-08
JP2017526342A (ja) 2017-09-14
PL3165523T3 (pl) 2020-07-13
WO2016003169A2 (ko) 2016-01-07
ES2768803T3 (es) 2020-06-23
CN106794172A (zh) 2017-05-31
US20170158642A1 (en) 2017-06-08
EP3165523A2 (en) 2017-05-10

Similar Documents

Publication Publication Date Title
EP4026835A3 (en) Pd-1/pd-l1 inhibitors
EP3675859A4 (en) COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES
WO2017100726A8 (en) Methods for treating huntington's disease
GEP20207147B (en) Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
WO2016172658A3 (en) Microbiome regulators and related uses thereof
WO2015197530A3 (en) Difluoromethyl-nicotinic-indanyl carboxamides
EP3934652A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES
EP3484504A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE
WO2015142001A3 (ko) 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
WO2016105525A3 (en) Novel pyrimidines as egfr inhibitors and methods of treating disorders
WO2017059385A8 (en) 11,13-modified saxitoxins for the treatment of pain
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
MX2016011898A (es) Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
EP3580208A4 (en) NOVEL HETEROCYCLIC COMPOUND, THEIR MANUFACTURING PROCESS AND PHARMACEUTICAL COMPOSITION WITH IT
EP3687540A4 (en) HETEROARYL COMPOUNDS USED AS CXCR4 INHIBITORS, COMPOSITION AND METHOD OF USE THEREOF
EP3279207A4 (en) Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof
EP4289822A3 (en) Benzoimidazol-1,2-yl amides as kv7 channel activators
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
EP4292652A3 (en) Compounds for the treatment of glycogen storage disorders
EA033460B1 (ru) Замещенные [1,2,4]триазольные соединения в качестве фунгицидов
SA518390788B1 (ar) مركب يستهدف إنترلوكين- 23 أ وعامل تنشيط الخلايا البائية واستخداماته
WO2016080796A3 (ko) 세스퀴테르펜 화합물을 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물 및 이의 용도
WO2016093554A3 (ko) 신규한 4-(아릴)-n-(2-알콕시티에노[3,2-b]피라진-3-일)-피페라진-1-카복스아미드 유도체 및 이의 항증식 효과
WO2015144652A3 (en) Heterocyclic compounds for the control of unwanted microorganisms
WO2018189661A3 (en) Methods and compounds for treating diabetes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15815352

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2016575756

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 15323342

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015815352

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015815352

Country of ref document: EP